1. Home
  2. ATRC vs EVO Comparison

ATRC vs EVO Comparison

Compare ATRC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATRC
  • EVO
  • Stock Information
  • Founded
  • ATRC 2000
  • EVO 1993
  • Country
  • ATRC United States
  • EVO Germany
  • Employees
  • ATRC N/A
  • EVO N/A
  • Industry
  • ATRC Medical/Dental Instruments
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATRC Health Care
  • EVO Health Care
  • Exchange
  • ATRC Nasdaq
  • EVO Nasdaq
  • Market Cap
  • ATRC 1.6B
  • EVO 1.6B
  • IPO Year
  • ATRC 2005
  • EVO 2021
  • Fundamental
  • Price
  • ATRC $32.96
  • EVO $3.23
  • Analyst Decision
  • ATRC Strong Buy
  • EVO Buy
  • Analyst Count
  • ATRC 10
  • EVO 2
  • Target Price
  • ATRC $48.50
  • EVO $5.90
  • AVG Volume (30 Days)
  • ATRC 639.5K
  • EVO 103.7K
  • Earning Date
  • ATRC 04-30-2025
  • EVO 05-21-2025
  • Dividend Yield
  • ATRC N/A
  • EVO N/A
  • EPS Growth
  • ATRC N/A
  • EVO N/A
  • EPS
  • ATRC N/A
  • EVO N/A
  • Revenue
  • ATRC $465,307,000.00
  • EVO $866,665,179.00
  • Revenue This Year
  • ATRC $14.60
  • EVO $3.70
  • Revenue Next Year
  • ATRC $12.58
  • EVO $10.32
  • P/E Ratio
  • ATRC N/A
  • EVO N/A
  • Revenue Growth
  • ATRC 16.55
  • EVO N/A
  • 52 Week Low
  • ATRC $18.94
  • EVO $2.85
  • 52 Week High
  • ATRC $43.11
  • EVO $7.98
  • Technical
  • Relative Strength Index (RSI)
  • ATRC 42.27
  • EVO 29.01
  • Support Level
  • ATRC $31.02
  • EVO $3.16
  • Resistance Level
  • ATRC $34.30
  • EVO $3.37
  • Average True Range (ATR)
  • ATRC 1.74
  • EVO 0.09
  • MACD
  • ATRC 0.07
  • EVO -0.00
  • Stochastic Oscillator
  • ATRC 42.08
  • EVO 13.46

About ATRC AtriCure Inc.

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: